Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUMATRIPTAN vs SUMATRIPTAN AND NAPROXEN SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve transmission.
Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of intracranial arteries and inhibiting trigeminal nerve transmission. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. The combination provides synergistic relief for migraine by targeting both neurogenic inflammation and vasodilation.
Acute treatment of migraine with or without aura,Acute treatment of cluster headache episodes
Acute treatment of migraine with or without aura in adults,Off-label: Acute treatment of cluster headache (sumatriptan component)
Sumatriptan is available as oral tablets (25 mg, 50 mg, 100 mg), subcutaneous injection (6 mg/0.5 m L), and nasal spray (5 mg, 20 mg). For acute migraine: oral: 50-100 mg at onset, may repeat after 2 hours (max 200 mg/day). Subcutaneous: 6 mg at onset, may repeat after 1 hour (max 12 mg/24h). Nasal spray: 20 mg in one nostril at onset, may repeat after 2 hours (max 40 mg/day).
Sumatriptan 85 mg/naproxen sodium 500 mg orally at onset of migraine; maximum one tablet per 24 hours.
2.5 hours (range 1–4 h); clinically relevant for redosing interval of ≥2 h.
Sumatriptan: 2.5 hours (range 2-4 hours); Naproxen: 12-17 hours (mean 14 hours). Clinical context: Sumatriptan half-life supports short dosing interval; Naproxen half-life allows twice-daily dosing for migraine prevention.
Primarily via monoamine oxidase A (MAO-A); minor via cytochrome P450 (CYP) enzymes.
Sumatriptan is metabolized primarily by monoamine oxidase A (MAO-A) to an indoleacetic acid metabolite. Naproxen sodium is metabolized by hepatic CYP enzymes (CYP1A2, CYP2C9) and other pathways, with glucuronidation.
60% renal (as indole acetic acid metabolite), 40% fecal; <3% unchanged in urine.
Sumatriptan: 57% renal (22% unchanged), 38% fecal; Naproxen: 95% renal (mostly as conjugated metabolites, <5% unchanged), <5% fecal.
14–21%, primarily to albumin and alpha-1-acid glycoprotein.
Sumatriptan: 14-21% (primarily albumin); Naproxen: >99% (albumin, extensively bound).
2.0–3.3 L/kg; indicates extensive tissue distribution.
Sumatriptan: 2.4 L/kg (suggests extensive tissue distribution); Naproxen: 0.16 L/kg (confined primarily to plasma and synovial fluid).
Oral: 15% (due to first-pass metabolism); subcutaneous: 97%; intranasal: 17% (with variability).
Sumatriptan: Oral 15% (due to first-pass metabolism), subcutaneous 96%, intranasal 17%; Naproxen: Oral >95% (nearly complete).
No specific dose adjustment is recommended for renal impairment. However, sumatriptan and its metabolites are excreted renally, and caution is advised in severe renal impairment (Cr Cl <15 m L/min). No specific GFR-based guidelines are established.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min); no adjustment recommended for mild to moderate impairment.
Contraindicated in severe hepatic impairment (Child-Pugh C). For mild to moderate hepatic impairment (Child-Pugh A or B): oral maximum dose is 50 mg; nasal spray: 5 mg single dose; subcutaneous: no specific adjustment, but caution advised due to reduced clearance.
Contraindicated in severe hepatic impairment (Child-Pugh class C); not recommended in moderate impairment (Child-Pugh class B); no adjustment for mild (Child-Pugh class A).
Not approved for pediatric use <18 years. However, off-label: adolescent (12-17 years): oral 25-100 mg at onset, may repeat after 2 hours (max 200 mg/day). Subcutaneous: 3-6 mg at onset (based on weight, e.g., 0.06 mg/kg). Nasal spray: 5-20 mg at onset.
Not recommended for patients under 18 years due to safety and efficacy not established.
Limited data in elderly. Start with the lowest effective dose (e.g., oral 25 mg, subcutaneous 3 mg, nasal spray 5 mg). Caution due to potential for cardiovascular risk, hypertension, and reduced hepatic/renal function. Avoid in patients with uncontrolled hypertension or ischemic heart disease.
Not recommended in patients ≥65 years due to increased risk of adverse events; no specific dosing adjustments available.
Not recommended for use in patients with risk factors for coronary artery disease (e.g., hypertension, diabetes, smoking) unless a cardiovascular evaluation confirms absence of coronary artery disease.
None
Risk of myocardial ischemia, infarction, and Prinzmetal's angina,Life-threatening serotonin syndrome with concomitant serotonergic drugs,Elevations in blood pressure,Increased risk of cerebrovascular events,Overuse headache with frequent use
Cardiovascular risk: Serious cardiovascular events including myocardial infarction, stroke, and coronary vasospasm, especially in patients with risk factors.,Gastrointestinal risk: NSAID-induced GI bleeding, ulceration, and perforation, particularly in elderly or those with prior GI history.,Hypertension: Elevation in blood pressure, including hypertensive crisis.,Serotonin syndrome: Risk when combined with other serotonergic drugs (e.g., SSRIs, MAOIs).,Renal toxicity: NSAIDs may impair renal function.,Anaphylaxis/allergic reactions: Immediate medical attention required.,Withdrawal headache: Overuse may lead to medication-overuse headache.
Ischemic heart disease,History of myocardial infarction,Uncontrolled hypertension,Hemiplegic or basilar migraine,Concomitant use of MAO-A inhibitors or within 2 weeks of discontinuation,Severe hepatic impairment,Hypersensitivity to sumatriptan
History of coronary artery disease, myocardial infarction, or ischemic heart disease,Coronary vasospasm (Prinzmetal's angina),Uncontrolled hypertension,Cerebrovascular disease (stroke or transient ischemic attack),Peripheral vascular disease,Hemiplegic or basilar migraine,Severe hepatic impairment,Third trimester of pregnancy,History of GI bleeding or perforation related to NSAID use,Active peptic ulcer disease,Concurrent use of MAO-A inhibitors or within 2 weeks of discontinuation,Hypersensitivity to sumatriptan, naproxen, or aspirin/other NSAIDs (including aspirin triad)
No significant food interactions. Avoid alcohol during migraine attacks as it can worsen headaches. May be taken with or without food.
No specific food restrictions, but avoid alcohol due to increased GI bleeding risk. May take with or without food. Food may delay absorption slightly but does not affect efficacy.
FDA Pregnancy Category C. In first trimester, no increased risk of major congenital malformations from available data; however, animal studies show embryo lethality and increased malformations at high doses. Second and third trimester risks include potential for uterine hypertonus and fetal hypoxia during maternal use for migraine attacks; avoid during third trimester due to risk of premature uterine contractions.
Sumatriptan: Human data do not show increased risk of major birth defects overall, but limited data in first trimester; animal studies show embryo/fetal toxicity at high doses. Naproxen: NSAIDs should be avoided after 30 weeks gestation due to risk of premature closure of ductus arteriosus and oligohydramnios; avoid in first and second trimesters unless clearly needed due to potential association with cardiac defects and miscarriage.
Sumatriptan is excreted into human breast milk with a relative infant dose of 3.5% of maternal weight-adjusted dose (M/P ratio approximately 0.6-4.3). Clinical studies show no adverse effects in breastfed infants; however, wait at least 12 hours after injection or 24 hours after oral dose to breastfeed to minimize exposure.
Sumatriptan: Excreted in breast milk in low amounts (M/P ratio 4.9); infant dose about 3.5% of maternal weight-adjusted dose; limited data show no adverse effects. Naproxen: Excreted in breast milk (M/P ratio 0.01-0.17); infant dose about 1-2% of maternal dose; use caution in premature infants or with prolonged use due to potential NSAID effects.
No specific dose adjustments required for pregnancy based on pharmacokinetic changes; however, lower starting doses may be considered due to increased sensitivity to vascular effects. Avoid use in preeclampsia or uncontrolled hypertension.
Sumatriptan: No dose adjustment recommended based on pharmacokinetic changes; however, consider lowest effective dose and avoid if possible first trimester. Naproxen: Avoid in pregnancy; if essential, use lowest effective dose for shortest duration. No pharmacokinetic data necessitating dose adjustment, but third trimester use is contraindicated.
Sumatriptan is a 5-HT1B/1D receptor agonist used for acute migraine. It is available in oral, nasal, subcutaneous, and rectal formulations. Onset of action is fastest with subcutaneous injection (10-15 minutes). Avoid use within 24 hours of other triptans or ergot alkaloids. Contraindicated in patients with ischemic heart disease, cerebrovascular disease, uncontrolled hypertension, or hemiplegic/basilar migraine. Monitor for serotonin syndrome when combined with SSRIs/SNRIs.
Combination tablet provides dual mechanism: sumatriptan (5-HT1B/1D agonist) and naproxen sodium (NSAID). Onset within 30 minutes. Maximum single dose: sumatriptan 85 mg/naproxen 500 mg. Risk of serotonin syndrome with other serotonergic drugs. Avoid in patients with ischemic heart disease, cerebrovascular disease, uncontrolled hypertension, or history of GI bleeding. Contraindicated within 24 hours of ergot alkaloids or other triptans. Renal dose adjustment necessary for Cr Cl <30 m L/min. Use lowest effective dose for shortest duration. Assess cardiovascular risk before prescribing. May cause drowsiness or dizziness.
Take sumatriptan at the first sign of migraine headache for best results.,Do not exceed the recommended dose: maximum 100 mg orally or 20 mg intranasally per single dose, with a maximum of 200 mg daily for oral formulations.,Seek emergency medical attention if you experience chest pain, shortness of breath, irregular heartbeat, or signs of stroke.,Avoid driving or operating machinery until you know how sumatriptan affects you, as it may cause dizziness or drowsiness.,Inform your doctor if you have heart disease, high blood pressure, or are pregnant or breastfeeding.
Take at the first sign of migraine; do not use to prevent migraines.,Do not exceed one tablet in 24 hours; wait at least 2 hours between doses.,Avoid alcohol, as it may increase risk of stomach bleeding.,Do not take with other NSAIDs (e.g., ibuprofen, aspirin) unless directed.,Seek emergency if chest pain, shortness of breath, sudden severe stomach pain, black/bloody stools, or signs of allergic reaction occur.,Avoid driving or operating machinery if drowsy or dizzy.,Notify doctor if you have heart disease, high blood pressure, liver/kidney disease, or are pregnant/nursing.
"Concurrent use of sumatriptan, a serotonin 5-HT1B/1D receptor agonist, and rasagiline, a selective monoamine oxidase B (MAO-B) inhibitor, can lead to serotonin syndrome due to excessive serotonergic activity in the central nervous system. Rasagiline inhibits the metabolism of serotonin, while sumatriptan indirectly increases serotonin release; their combination may result in life-threatening neuromuscular excitation, autonomic instability, and altered mental status. Symptoms may include hyperthermia, rigidity, myoclonus, and rapid fluctuations in vital signs, requiring immediate medical intervention."
"Sumatriptan, a 5-HT1B/1D receptor agonist used for migraine, and sulpiride, a dopamine D2 receptor antagonist with atypical antipsychotic properties, may exhibit additive or synergistic effects on the central nervous system. This combination can potentially increase the risk of serotonin syndrome (due to sumatriptan's serotonergic activity) and may also lead to enhanced extrapyramidal symptoms or neuroleptic malignant syndrome via combined dopaminergic antagonism. Clinical outcomes may include hyperthermia, rigidity, altered mental status, and autonomic instability."
"The combination of sumatriptan (a 5-HT1B/1D receptor agonist) and paroxetine (a selective serotonin reuptake inhibitor) increases the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. This interaction is due to additive serotonergic effects, as both drugs enhance serotonin activity in the central nervous system. Clinical outcomes range from mild symptoms (tremor, hyperreflexia, diaphoresis) to severe manifestations (hyperthermia, rigidity, seizures) and require immediate medical attention."
"Naproxen and meloxicam are both nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) enzymes, leading to decreased synthesis of prostaglandins, prostacyclin, and thromboxanes. Concomitant use increases the risk of dose-dependent adverse effects, particularly gastrointestinal ulceration, bleeding, and perforation, as well as renal impairment, due to additive inhibition of protective prostaglandins in the gut and kidney. Clinically, this combination may result in acute kidney injury, anemia from occult gastrointestinal bleeding, or life-threatening perforation, especially in elderly patients or those with pre-existing renal disease or peptic ulcer history."
"Bevantolol, a beta-1 selective adrenergic receptor antagonist, reduces cardiac output and suppresses renin release, thereby lowering blood pressure. Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, leading to decreased synthesis of vasodilatory prostaglandins and enhanced sodium and water retention. The net effect is an attenuation of bevantolol's antihypertensive efficacy, potentially resulting in elevated blood pressure and reduced cardiovascular protection."
"Betaxolol, a beta-1 selective adrenergic receptor antagonist, may reduce the antihypertensive efficacy of naproxen, a nonsteroidal anti-inflammatory drug (NSAID). Naproxen inhibits cyclooxygenase (COX) enzymes, leading to decreased synthesis of vasodilatory prostaglandins (e.g., prostacyclin) in the renal and vascular endothelium. This can result in sodium and fluid retention, increased systemic vascular resistance, and blunting of the blood pressure-lowering effects of beta-blockers like betaxolol, potentially compromising hypertension control."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUMATRIPTAN vs SUMATRIPTAN AND NAPROXEN SODIUM, answered by our medical review team.
SUMATRIPTAN is a 5-HT1 Agonist that works by Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve transmission.. SUMATRIPTAN AND NAPROXEN SODIUM is a 5-HT1 Agonist that works by Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of intracranial arteries and inhibiting trigeminal nerve transmission. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. The combination provides synergistic relief for migraine by targeting both neurogenic inflammation and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUMATRIPTAN and SUMATRIPTAN AND NAPROXEN SODIUM depend on the specific clinical indication. These are both 5-HT1 Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUMATRIPTAN is: Sumatriptan is available as oral tablets (25 mg, 50 mg, 100 mg), subcutaneous injection (6 mg/0.5 m L), and nasal spray (5 mg, 20 mg). For acute migraine: oral: 50-100 mg at onset, may repeat after 2 hours (max 200 mg/day). Subcutaneous: 6 mg at onset, may repeat after 1 hour (max 12 mg/24h). Nasal spray: 20 mg in one nostril at onset, may repeat after 2 hours (max 40 mg/day).. The standard adult dose of SUMATRIPTAN AND NAPROXEN SODIUM is: Sumatriptan 85 mg/naproxen sodium 500 mg orally at onset of migraine; maximum one tablet per 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUMATRIPTAN and SUMATRIPTAN AND NAPROXEN SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUMATRIPTAN is classified as Category D/X. FDA Pregnancy Category C. In first trimester, no increased risk of major congenital malformations from available data; however, animal studies show embryo lethality and increased m. SUMATRIPTAN AND NAPROXEN SODIUM is classified as Category D/X. Sumatriptan: Human data do not show increased risk of major birth defects overall, but limited data in first trimester; animal studies show embryo/fetal toxicity at high doses. Nap. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.